{"id":53353,"date":"2023-09-20T09:45:18","date_gmt":"2023-09-20T09:45:18","guid":{"rendered":"https:\/\/medsname.com\/keytruda\/"},"modified":"2026-04-30T10:25:12","modified_gmt":"2026-04-30T10:25:12","slug":"keytruda","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/keytruda\/","title":{"rendered":"Keytruda"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Keytruda?<\/h3>\n<p style=\"margin:0;\"><strong>Keytruda<\/strong> je <strong>intraven\u00f3zn\u00ed infuze<\/strong> od spole\u010dnosti Merck (MSD) obsahuj\u00edc\u00ed <strong>pembrolizumab 100 mg\/4 mL<\/strong> \u2014 humanizovan\u00e1 monoklon\u00e1ln\u00ed protil\u00e1tka a <strong>inhibitor imunitn\u00edho checkpointu PD-1<\/strong>. Pembrolizumab odstra\u0148uje blok\u00e1du imunitn\u00edho syst\u00e9mu v rozpozn\u00e1v\u00e1n\u00ed n\u00e1dorov\u00fdch bun\u011bk. Schv\u00e1len pro <strong>mnoho typ\u016f n\u00e1dor\u016f<\/strong>: pokro\u010dil\u00fd melanom, nemalobun\u011b\u010dn\u00fd karcinom plic (NSCLC), dla\u017edicobun\u011b\u010dn\u00fd karcinom hlavy a krku, klasick\u00fd Hodgkin\u016fv lymfom, uroteli\u00e1ln\u00ed karcinom, MSI-H\/dMMR n\u00e1dory (jak\u00fdkoli typ n\u00e1doru), karcinom \u017ealudku, karcinom j\u00edcnu, karcinom d\u011blo\u017en\u00edho hrdla, hepatocelul\u00e1rn\u00ed karcinom, karcinom ledvinov\u00fdch bun\u011bk, karcinom endometria, trojnegativn\u00ed karcinom prsu a n\u011bkolik dal\u0161\u00edch. Standardn\u00ed d\u00e1vka pro dosp\u011bl\u00e9: <strong>200 mg intraven\u00f3zn\u011b ka\u017ed\u00e9 3 t\u00fddny<\/strong> NEBO <strong>400 mg intraven\u00f3zn\u011b ka\u017ed\u00fdch 6 t\u00fddn\u016f<\/strong>, pod\u00e1v\u00e1no infuz\u00ed po dobu 30 minut. <strong>Pod\u00e1v\u00e1 se v\u00fdhradn\u011b v nemocnici nebo v infuzn\u00edm centru onkologick\u00e9 denn\u00ed p\u00e9\u010de vy\u0161kolen\u00fdm person\u00e1lem \u2014 nen\u00ed ur\u010deno k samopod\u00e1n\u00ed.<\/strong> Hlavn\u00ed rizika: <strong>imunitn\u011b zprost\u0159edkovan\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (irAEs)<\/strong> \u2014 m\u016f\u017ee postihnout jak\u00fdkoli org\u00e1nov\u00fd syst\u00e9m (pneumonitida, kolitida, hepatitida, endokrinopatie, ko\u017en\u00ed reakce, nefritida, neuropatie) a m\u016f\u017ee vy\u017eadovat syst\u00e9mov\u00e9 kortikosteroidy a trval\u00e9 ukon\u010den\u00ed l\u00e9\u010dby.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Vy\u017eaduje se odborn\u00fd dohled.<\/strong> L\u00e9ky na rakovinu mus\u00ed b\u00fdt p\u0159edeps\u00e1ny o\u0161et\u0159uj\u00edc\u00edm onkologem s potvrzenou diagn\u00f3zou, vstupn\u00edm stagingem a definovan\u00fdm l\u00e9\u010debn\u00fdm pl\u00e1nem. Nikdy neza\u010d\u00ednejte, nep\u0159eru\u0161ujte, nem\u011b\u0148te d\u00e1vkov\u00e1n\u00ed ani neu\u017e\u00edvejte l\u00e9ky na rakovinu mimo onkologick\u00fd l\u00e9\u010debn\u00fd pl\u00e1n. V\u011bt\u0161ina l\u00e9k\u016f na rakovinu vy\u017eaduje pravideln\u00e9 monitorov\u00e1n\u00ed krevn\u00edch test\u016f (krevn\u00ed obraz, jatern\u00ed testy, funkce ledvin), je absolutn\u011b kontraindikov\u00e1na v t\u011bhotenstv\u00ed a m\u00e1 v\u00fdznamn\u00e9 l\u00e9kov\u00e9 interakce.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 \u0160ifrovan\u00e9 platby<\/strong> \u00b7 <strong>\ud83d\udcb3 Ov\u011b\u0159en\u00fd platebn\u00ed procesor<\/strong> \u00b7 <strong>\ud83d\ude9a Doprava do cel\u00e9ho sv\u011bta<\/strong> \u00b7 <strong>\u2b50 4,9\/5 od 1 400+ z\u00e1kazn\u00edk\u016f<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">Co je Keytruda?<\/h2>\n<p>Keytruda (<strong>pembrolizumab<\/strong>) je humanizovan\u00e1 monoklon\u00e1ln\u00ed protil\u00e1tka IgG4 od spole\u010dnosti Merck (MSD), kter\u00e1 c\u00edl\u00ed na <strong>programmed cell death protein 1 (PD-1)<\/strong> receptor na T-bu\u0148k\u00e1ch. Blokov\u00e1n\u00edm PD-1 pembrolizumab uvol\u0148uje imunitn\u00ed brzdy, kter\u00e9 n\u00e1dorov\u00e9 bu\u0148ky vyu\u017e\u00edvaj\u00ed k \u00faniku p\u0159ed imunitn\u00edm syst\u00e9mem. Schv\u00e1leno FDA v roce 2014, Keytruda je nyn\u00ed indikov\u00e1na pro v\u00edce typ\u016f rakoviny ne\u017e jak\u00e1koli jin\u00e1 imunoterapie a z\u00e1sadn\u011b zm\u011bnila l\u00e9\u010dbu pokro\u010dil\u00e9ho melanomu, pokro\u010dil\u00e9ho NSCLC a mnoha dal\u0161\u00edch typ\u016f n\u00e1dor\u016f.<\/p>\n<p>Pembrolizumab je dod\u00e1v\u00e1n jako <strong>koncentrovan\u00fd roztok pro infuzi (100 mg\/4 mL lahvi\u010dka)<\/strong> kter\u00fd se \u0159ed\u00ed v norm\u00e1ln\u00edm fyziologick\u00e9m roztoku nebo 5% gluk\u00f3ze a pod\u00e1v\u00e1 se jako pomal\u00e1 intraven\u00f3zn\u00ed infuze po dobu 30 minut v nemocnici nebo onkologick\u00e9 denn\u00ed jednotce. Je <strong>ne<\/strong> dostupn\u00e9 v peror\u00e1ln\u00ed form\u011b a nelze je pod\u00e1vat samostatn\u011b.<\/p>\n<h2 class=\"wp-block-heading\">Jak Keytruda funguje?<\/h2>\n<p>Rakovinn\u00e9 bu\u0148ky \u010dasto exprimuj\u00ed <strong>PD-L1<\/strong> ligand na sv\u00e9m povrchu. Kdy\u017e se PD-L1 nav\u00e1\u017ee na <strong>PD-1<\/strong> receptor na T-bu\u0148ce infiltruj\u00edc\u00ed n\u00e1dor, signalizuje T-bu\u0148ce, aby ustoupila \u2013 \u010d\u00edm\u017e efektivn\u011b vypne imunitn\u00ed odpov\u011b\u010f proti n\u00e1doru. Pembrolizumab je navr\u017een tak, aby blokoval tuto interakci PD-1 \/ PD-L1:<\/p>\n<ul>\n<li><strong>Uvol\u0148uje imunitn\u00ed brzdu<\/strong> \u2014 blok\u00e1da PD-1 umo\u017e\u0148uje n\u00e1dorov\u011b specifick\u00fdm T-bu\u0148k\u00e1m rozpoznat a zab\u00edt rakovinn\u00e9 bu\u0148ky.<\/li>\n<li><strong>Exprese PD-L1 v n\u00e1doru \u010dasto p\u0159edpov\u00edd\u00e1 odpov\u011b\u010f<\/strong> \u2014 n\u00e1dory s vysokou expres\u00ed PD-L1 (TPS \u2265 50%) reaguj\u00ed \u010dast\u011bji ne\u017e n\u00e1dory negativn\u00ed na PD-L1, zejm\u00e9na u NSCLC. N\u011bkter\u00e9 indikace vy\u017eaduj\u00ed testov\u00e1n\u00ed PD-L1 p\u0159ed l\u00e9\u010dbou.<\/li>\n<li><strong>MSI-H \/ dMMR n\u00e1dory reaguj\u00ed nez\u00e1visle na PD-L1<\/strong> \u2014 n\u00e1dory s poruchou opravy p\u00e1rov\u00e1n\u00ed b\u00e1z\u00ed nebo mikrosatelitovou nestabilitou vysoce reaguj\u00ed na blok\u00e1du kontroln\u00edho bodu bez ohledu na stav PD-L1. Keytruda m\u00e1 n\u00e1dorov\u011b agnostickou indikaci pro MSI-H\/dMMR n\u00e1dory.<\/li>\n<li><strong>N\u00e1dorov\u00e1 muta\u010dn\u00ed z\u00e1t\u011b\u017e (TMB)<\/strong> \u2014 n\u00e1dory s vysokou TMB generuj\u00ed v\u00edce neoantigen\u016f, kter\u00e9 imunitn\u00ed syst\u00e9m m\u016f\u017ee rozpoznat; n\u011bkter\u00e9 indikace Keytrudy pou\u017e\u00edvaj\u00ed TMB \u2265 10 mut\/Mb jako biomarker.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Pou\u017eit\u00ed a indikace<\/h2>\n<p>Keytruda je schv\u00e1lena hlavn\u00edmi regula\u010dn\u00edmi org\u00e1ny (FDA, EMA, MHRA a dal\u0161\u00edmi) pro neobvykle \u0161irok\u00e9 spektrum onkologick\u00fdch onemocn\u011bn\u00ed. Mezi hlavn\u00ed indikace u dosp\u011bl\u00fdch pat\u0159\u00ed:<\/p>\n<ul>\n<li><strong>Melanom<\/strong> \u2014 neresekovateln\u00fd pokro\u010dil\u00fd nebo metastatick\u00fd; adjuvantn\u00ed l\u00e9\u010dba po kompletn\u00ed resekci ve stadiu IIB\/IIC\/III<\/li>\n<li><strong>Nemalobun\u011b\u010dn\u00fd karcinom plic (NSCLC)<\/strong> \u2014 prvn\u00ed linie monoterapie u metastatick\u00e9ho NSCLC s PD-L1 TPS \u2265 50 %; prvn\u00ed linie v kombinaci s chemoterapi\u00ed bez ohledu na PD-L1; druh\u00e1 linie monoterapie pro PD-L1 \u2265 1 %; adjuvantn\u00ed l\u00e9\u010dba po resekci<\/li>\n<li><strong>Spinocelul\u00e1rn\u00ed karcinom hlavy a krku (HNSCC)<\/strong> \u2014 prvn\u00ed linie metastatick\u00e9ho\/recidivuj\u00edc\u00edho (s chemoterapi\u00ed nebo bez n\u00ed)<\/li>\n<li><strong>Klasick\u00fd Hodgkin\u016fv lymfom<\/strong> \u2014 relabuj\u00edc\u00ed nebo refraktern\u00ed po v\u00edce\u010detn\u00e9 chemoterapii<\/li>\n<li><strong>Uroteli\u00e1ln\u00ed karcinom<\/strong> \u2014 prvn\u00ed linie metastatick\u00e9ho u pacient\u016f nezp\u016fsobil\u00fdch pro cisplatina; druh\u00e1 linie po chemoterapii platina; vysoce rizikov\u00fd nemuskul\u00e1rn\u011b invazivn\u00ed karcinom mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e (nereaguj\u00edc\u00ed na BCG)<\/li>\n<li><strong>MSI-H\/dMMR n\u00e1dory<\/strong> \u2014 indikace nez\u00e1visl\u00e1 na typu tumoru pro jak\u00fdkoli solidn\u00ed n\u00e1dor s vysokou mikrosatelitn\u00ed nestabilitou (MSI-high) nebo defektem opravy p\u00e1rov\u00e1n\u00ed b\u00e1z\u00ed (mismatch-repair-deficient); zvl\u00e1\u0161t\u011b v\u00fdznamn\u00e9 u kolorekt\u00e1ln\u00edho, endometri\u00e1ln\u00edho a \u017ealude\u010dn\u00edho karcinomu<\/li>\n<li><strong>\u017dalude\u010dn\u00ed karcinom a karcinom gastroezofage\u00e1ln\u00edho p\u0159echodu<\/strong> \u2014 prvn\u00ed linie HER2+ (s chemoterapi\u00ed) a HER2- (s chemoterapi\u00ed)<\/li>\n<li><strong>Rakovina j\u00edcnu<\/strong><\/li>\n<li><strong>Rakovina d\u011blo\u017en\u00edho \u010d\u00edpku<\/strong> \u2014 prvn\u00ed linie PD-L1+ perzistentn\u00ed, recidivuj\u00edc\u00ed nebo metastatick\u00e1 (s chemoterapi\u00ed \u00b1 bevacizumab)<\/li>\n<li><strong>Hepatocelul\u00e1rn\u00ed karcinom (j\u00e1tra)<\/strong><\/li>\n<li><strong>Rakovina ledvinov\u00fdch bun\u011bk<\/strong> \u2014 prvn\u00ed linie v kombinaci s axitinibem nebo lenvatinibem<\/li>\n<li><strong>Rakovina endometria<\/strong> \u2014 pMMR (s lenvatinibem) a dMMR\/MSI-H (monoterapie)<\/li>\n<li><strong>Triple-negativn\u00ed karcinom prsu (TNBC)<\/strong> \u2014 vysok\u00e9 riziko \u010dasn\u00e9ho stadia neoadjuvantn\u00ed (s chemoterapi\u00ed) a metastatick\u00e1 PD-L1+ (CPS \u2265 10)<\/li>\n<li><strong>Kut\u00e1nn\u00ed spinocelul\u00e1rn\u00ed karcinom<\/strong>, Merkel\u016fv bun\u011b\u010dn\u00fd karcinom, prim\u00e1rn\u00ed mediastin\u00e1ln\u00ed velkobun\u011b\u010dn\u00fd B-lymfom a n\u011bkolik vz\u00e1cn\u00fdch n\u00e1dorov\u011b agnostick\u00fdch indikac\u00ed<\/li>\n<\/ul>\n<p>Spr\u00e1vn\u00e1 indikace a kombinace p\u0159\u00edpravku Keytruda z\u00e1vis\u00ed na typu n\u00e1doru, stadiu, stavu biomarker\u016f (PD-L1 TPS nebo CPS, MSI\/dMMR, TMB, HER2) a p\u0159edchoz\u00ed l\u00e9\u010db\u011b. <strong>Toto rozhodnut\u00ed pat\u0159\u00ed do kompetence specialisty-onkologa po dokon\u010den\u00ed patologick\u00e9ho a biomarkerov\u00e9ho vy\u0161et\u0159en\u00ed.<\/strong><\/p>\n<h2 class=\"wp-block-heading\">D\u00e1vkov\u00e1n\u00ed a pod\u00e1v\u00e1n\u00ed p\u0159\u00edpravku Keytruda<\/h2>\n<p>Standardn\u00ed d\u00e1vkov\u00e1n\u00ed pro dosp\u011bl\u00e9:<\/p>\n<ul>\n<li><strong>200 mg intraven\u00f3zn\u00ed infuze ka\u017ed\u00e9 3 t\u00fddny<\/strong> (p\u016fvodn\u00ed sch\u00e9ma) NEBO<\/li>\n<li><strong>400 mg intraven\u00f3zn\u00ed infuze ka\u017ed\u00fdch 6 t\u00fddn\u016f<\/strong> (ploch\u00e9 d\u00e1vkov\u00e1n\u00ed Q6W \u2013 stejn\u00e1 \u00fa\u010dinnost s m\u00e9n\u011b \u010dast\u00fdmi n\u00e1v\u0161t\u011bvami)<\/li>\n<li>D\u011btsk\u00e1 d\u00e1vka: 2 mg\/kg (maxim\u00e1ln\u011b 200 mg) intraven\u00f3zn\u011b ka\u017ed\u00e9 3 t\u00fddny<\/li>\n<li>Ka\u017ed\u00e1 infuze se pod\u00e1v\u00e1 po dobu <strong>30 minut<\/strong> p\u0159es in-line filtr 0,2\u20135 \u00b5m<\/li>\n<\/ul>\n<h3 class=\"wp-block-heading\">Zp\u016fsob pod\u00e1v\u00e1n\u00ed p\u0159\u00edpravku Keytruda<\/h3>\n<ol>\n<li><strong>Pouze v nemocni\u010dn\u00edm nebo onkologick\u00e9m denn\u00edm stacion\u00e1\u0159i.<\/strong> Keytruda je pod\u00e1v\u00e1n vy\u0161kolen\u00fdm o\u0161et\u0159ovatelsk\u00fdm nebo l\u00e9ka\u0159sk\u00fdm person\u00e1lem pod dohledem specialisty onkologa \u2014 nikdy nen\u00ed ur\u010den k samopod\u00e1n\u00ed nebo pod\u00e1n\u00ed v komunitn\u00edm prost\u0159ed\u00ed.<\/li>\n<li><strong>P\u0159\u00edprava p\u0159ed infuz\u00ed<\/strong> p\u0159i ka\u017ed\u00e9m cyklu: kompletn\u00ed krevn\u00ed obraz, komplexn\u00ed metabolick\u00fd panel (jatern\u00ed testy, ren\u00e1ln\u00ed funkce), funkce \u0161t\u00edtn\u00e9 \u017el\u00e1zy (TSH, voln\u00fd T4) ka\u017ed\u00fdch 6 t\u00fddn\u016f, hladina gluk\u00f3zy v krvi. Screening p\u0159\u00edznak\u016f nov\u00fdch imunitn\u011b zprost\u0159edkovan\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f.<\/li>\n<li><strong>P\u0159edmedikace obvykle NEN\u00cd vy\u017eadov\u00e1na<\/strong> \u2014 pembrolizumab nezp\u016fsobuje typickou nevolnost spojenou s chemoterapi\u00ed nebo hypersenzitivn\u00ed reakce. Antiemetika nejsou pot\u0159eba.<\/li>\n<li><strong>P\u0159\u00edprava lahvi\u010dky:<\/strong> na\u0159e\u010fte pembrolizumab v norm\u00e1ln\u00edm soln\u00e9m roztoku nebo 5% gluk\u00f3ze na kone\u010dnou koncentraci 1\u201310 mg\/ml. Pou\u017eijte do 6 hodin od p\u0159\u00edpravy, pokud je skladov\u00e1n p\u0159i pokojov\u00e9 teplot\u011b, nebo do 24 hodin, pokud je chlazen.<\/li>\n<li><strong>30minutov\u00e1 intraven\u00f3zn\u00ed infuze<\/strong> pomoc\u00ed inline filtru 0,2\u20135 \u00b5m. Nen\u00ed ur\u010deno k intraven\u00f3zn\u00edmu pushu nebo bolusu.<\/li>\n<li><strong>Frekvence cykl\u016f<\/strong> podle pl\u00e1nu (Q3W nebo Q6W). Pokra\u010dujte a\u017e do progrese onemocn\u011bn\u00ed, nesnesiteln\u00e9 toxicity nebo dokon\u010den\u00ed pl\u00e1novan\u00e9 doby l\u00e9\u010dby (obvykle 24 m\u011bs\u00edc\u016f v adjuvantn\u00edm re\u017eimu; a\u017e do progrese u metastatick\u00e9ho onemocn\u011bn\u00ed).<\/li>\n<li><strong>Povinn\u00e9 monitorov\u00e1n\u00ed<\/strong> p\u0159i ka\u017ed\u00e9 n\u00e1v\u0161t\u011bv\u011b sledujte imunitn\u011b zprost\u0159edkovan\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky: k\u016f\u017ee (vyr\u00e1\u017eka, vitiligo, dermatitida), GI (pr\u016fjem, bolesti b\u0159icha), d\u00fdchac\u00ed (ka\u0161el, du\u0161nost), endokrinn\u00ed (\u00fanava, zm\u011bna hmotnosti, palpitace zp\u016fsoben\u00e9 tyreoiditidou nebo hypofyzitidou), j\u00e1tra (\u017eloutenka), ledviny (kreatinin), neurologick\u00e9 (slabost, parestezie).<\/li>\n<li><strong>Trval\u00e9 ukon\u010den\u00ed l\u00e9\u010dby<\/strong> u irAEs stupn\u011b 3\u20134 pneumonitidy, hepatitidy, nefritidy, dermatitidy, neurotoxicity, myokarditidy; opakovan\u00fdch irAEs stupn\u011b 2\u20133 jak\u00e9hokoli syst\u00e9mu; nebo jak\u00e9hokoli irAE stupn\u011b 4.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Ne\u017e\u00e1douc\u00ed \u00fa\u010dinky Keytrudy<\/h2>\n<p>Pembrolizumab m\u00e1 z\u00e1sadn\u011b odli\u0161n\u00fd toxick\u00fd profil ne\u017e cytotoxick\u00e1 chemoterapie. Dominantn\u00ed kategori\u00ed vedlej\u0161\u00edch \u00fa\u010dink\u016f jsou <strong>imunitn\u011b zprost\u0159edkovan\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (irAEs)<\/strong> \u2014 autoimunitn\u00ed reakce zp\u016fsoben\u00e9 nekontrolovanou imunitn\u00ed aktivitou proti norm\u00e1ln\u00edm tk\u00e1n\u00edm.<\/p>\n<p><strong>B\u011b\u017en\u00e9 (ne-irAE):<\/strong> \u00fanava, sn\u00ed\u017een\u00e1 chu\u0165 k j\u00eddlu, nevolnost (m\u00edrn\u00e1), z\u00e1cpa, pr\u016fjem, artralgie, sv\u011bd\u011bn\u00ed, vyr\u00e1\u017eka, m\u00edrn\u00e1 bolest hlavy.<\/p>\n<p><strong>B\u011b\u017en\u00e9 imunitn\u011b zprost\u0159edkovan\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (irAEs):<\/strong><\/p>\n<ul>\n<li><strong>Hypotyre\u00f3za<\/strong> (10\u201315%) a hypertyre\u00f3za (4\u20136%) \u2014 zp\u016fsoben\u00e9 imunitn\u00ed tyreoiditidou. Obvykle vy\u017eaduje celo\u017eivotn\u00ed substituci levothyroxinem. Kontrola TSH ka\u017ed\u00fdch 6 t\u00fddn\u016f.<\/li>\n<li><strong>Ko\u017en\u00ed reakce<\/strong> \u2014 vyr\u00e1\u017eka, sv\u011bd\u011bn\u00ed, vitiligo, lichenoidn\u00ed erupce. T\u011b\u017ek\u00e9 v 1\u20133%.<\/li>\n<li><strong>Pr\u016fjem \/ kolitida<\/strong> \u2014 1\u20133% t\u011b\u017ek\u00fdch p\u0159\u00edpad\u016f. Riziko perforace st\u0159eva p\u0159i nel\u00e9\u010den\u00ed.<\/li>\n<li><strong>Pneumonitida<\/strong> (~3% jak\u00e9hokoli stupn\u011b, &lt;1% z\u00e1va\u017en\u00e9) \u2014 nov\u011b vznikl\u00e1 du\u0161nost nebo ka\u0161el vy\u017eaduj\u00ed urgentn\u00ed CT hrudn\u00edku.<\/li>\n<li><strong>Hepatitida<\/strong> (~1% z\u00e1va\u017en\u00e9) \u2014 zv\u00fd\u0161en\u00ed jatern\u00edch test\u016f.<\/li>\n<li><strong>Adren\u00e1ln\u00ed insuficience, hypofyzitida<\/strong> \u2014 \u00fanava, hypotenze, hyponatr\u00e9mie. M\u016f\u017ee vy\u017eadovat celo\u017eivotn\u00ed substituci kortikosteroidy.<\/li>\n<li><strong>Diabetes 1. typu<\/strong> \u2014 nov\u011b vznikl\u00e1 ketoacid\u00f3za. V\u011bt\u0161inou nevratn\u00fd; celo\u017eivotn\u00ed inzulin.<\/li>\n<li><strong>Nefritida<\/strong> \u2014 vzestup kreatininu.<\/li>\n<\/ul>\n<p><strong>M\u00e9n\u011b \u010dast\u00e9, ale v\u00fdznamn\u00e9 imunitn\u011b zprost\u0159edkovan\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky:<\/strong> myokarditida (vz\u00e1cn\u00e9, ale s vysokou mortalitou), perifern\u00ed a krani\u00e1ln\u00ed neuropatie, Guillain-Barr\u00e9ho syndrom, myasthenia gravis, encefalitida, polymyalgie, uveitida, z\u00e1va\u017en\u00e9 ko\u017en\u00ed reakce (Stevens-Johnson\u016fv syndrom, TEN), hemolytick\u00e1 an\u00e9mie, cytopenie.<\/p>\n<p><strong>Kl\u00ed\u010dov\u00fd princip l\u00e9\u010dby imunitn\u011b zprost\u0159edkovan\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f:<\/strong> stupe\u0148 1 \u0159e\u0161it podp\u016frnou p\u00e9\u010d\u00ed + monitorov\u00e1n\u00edm; stupe\u0148 2 p\u0159eru\u0161it l\u00e9\u010dbu + zah\u00e1jit syst\u00e9mov\u00e9 kortikosteroidy (prednison 0,5\u20131 mg\/kg); stupe\u0148 3\u20134 p\u0159eru\u0161it nebo trvale ukon\u010dit + vysok\u00e9 d\u00e1vky kortikosteroid\u016f (1\u20132 mg\/kg) + konzultace specialisty (endokrinologie\/GI\/pl\u00edce\/kardiologie) dle pot\u0159eby. V\u011bt\u0161ina imunitn\u011b zprost\u0159edkovan\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f se zlep\u0161\u00ed p\u0159i v\u010dasn\u00e9 steroidn\u00ed terapii. Endokrinopatie (\u0161t\u00edtn\u00e1 \u017el\u00e1za, nadledviny, diabetes 1. typu) jsou obvykle trval\u00e9 a vy\u017eaduj\u00ed celo\u017eivotn\u00ed hormon\u00e1ln\u00ed substituci.<\/p>\n<h2 class=\"wp-block-heading\">Varov\u00e1n\u00ed a opat\u0159en\u00ed<\/h2>\n<ul>\n<li><strong>Imunitn\u011b zprost\u0159edkovan\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky:<\/strong> mohou postihnout jak\u00fdkoli org\u00e1nov\u00fd syst\u00e9m, mohou se objevit kdykoli b\u011bhem l\u00e9\u010dby (v\u010detn\u011b m\u011bs\u00edc\u016f po ukon\u010den\u00ed). Vzd\u011bl\u00e1v\u00e1n\u00ed pacient\u016f a pe\u010dovatel\u016f o p\u0159\u00edznac\u00edch imunitn\u011b zprost\u0159edkovan\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f je povinn\u00e9. Pacienti mus\u00ed vyhledat p\u00e9\u010di je\u0161t\u011b tent\u00fd\u017e den p\u0159i: t\u011b\u017ek\u00e9m pr\u016fjmu (&gt;4 stolice nad b\u011b\u017enou frekvenci), nov\u011b vznikl\u00e9m zkr\u00e1cen\u00ed dechu, t\u011b\u017ek\u00e9 \u00fanav\u011b s hypotenz\u00ed, \u017eloutence, siln\u00e9 bolesti b\u0159icha, bolesti na hrudi, slabosti nebo necitlivosti, t\u011b\u017ek\u00e9 ko\u017en\u00ed vyr\u00e1\u017ece nebo nov\u00e9 bolesti hlavy se zm\u011bnami vid\u011bn\u00ed.<\/li>\n<li><strong>P\u0159edexistuj\u00edc\u00ed autoimunitn\u00ed onemocn\u011bn\u00ed<\/strong> (nap\u0159. z\u00e1n\u011btliv\u00e9 st\u0159evn\u00ed onemocn\u011bn\u00ed, lupus, revmatoidn\u00ed artritida, psori\u00e1za, roztrou\u0161en\u00e1 skler\u00f3za, diabetes 1. typu): Keytruda m\u016f\u017ee v\u00fdrazn\u011b zhor\u0161it z\u00e1kladn\u00ed onemocn\u011bn\u00ed. Rozhodnut\u00ed o pom\u011bru rizika a p\u0159\u00ednosu mus\u00ed prov\u00e9st onkolog spolu s p\u0159\u00edslu\u0161n\u00fdm specialistou.<\/li>\n<li><strong>P\u0159\u00edjemci transplantovan\u00fdch pevn\u00fdch org\u00e1n\u016f nebo kmenov\u00fdch bun\u011bk:<\/strong> Keytruda m\u016f\u017ee vyvolat odm\u00edtnut\u00ed transplant\u00e1tu nebo reakci \u0161t\u011bpu proti hostiteli. Je nutn\u00fd odborn\u00fd dohled.<\/li>\n<li><strong>T\u011bhotenstv\u00ed:<\/strong> kontraindikov\u00e1no \u2014 pembrolizumab proch\u00e1z\u00ed placentou a m\u016f\u017ee naru\u0161it fet\u00e1ln\u00ed imunitn\u00ed toleranci, co\u017e vede k potratu nebo autoimunitn\u00edm komplikac\u00edm. Spolehliv\u00e1 antikoncepce po celou dobu l\u00e9\u010dby a 4 m\u011bs\u00edce po posledn\u00ed d\u00e1vce.<\/li>\n<li><strong>Kojen\u00ed:<\/strong> vyvarujte se \u2014 imunoglobuliny se vylu\u010duj\u00ed do mate\u0159sk\u00e9ho ml\u00e9ka. Po\u010dkejte 4 m\u011bs\u00edce po posledn\u00ed d\u00e1vce.<\/li>\n<li><strong>\u017div\u00e9 vakc\u00edny:<\/strong> kontraindikov\u00e1no.<\/li>\n<li><strong>Aktivn\u00ed infekce:<\/strong> p\u0159eru\u0161te b\u011bhem z\u00e1va\u017en\u00e9 infekce.<\/li>\n<li><strong>T\u011b\u017ek\u00e9 jatern\u00ed\/ledvinov\u00e9 posti\u017een\u00ed:<\/strong> omezen\u00e9 \u00fadaje; rozhodnut\u00ed specialisty.<\/li>\n<li><strong>Skladov\u00e1n\u00ed v chladn\u00e9m \u0159et\u011bzci:<\/strong> lahvi\u010dky mus\u00ed b\u00fdt uchov\u00e1v\u00e1ny v chladni\u010dce p\u0159i 2\u20138\u00b0C a nesm\u00ed b\u00fdt zmra\u017eeny. Poru\u0161en\u00ed chladov\u00e9ho \u0159et\u011bzce invaliduje lahvi\u010dku.<\/li>\n<li><strong>N\u00e1klady a \u00fahrada:<\/strong> Keytruda je jedn\u00edm z nejdra\u017e\u0161\u00edch protin\u00e1dorov\u00fdch l\u00e9k\u016f (~10 000\u201314 000 USD za d\u00e1vku p\u0159i p\u016fvodn\u00ed cen\u011b). Programy pacient\u016f, biosimil\u00e1rn\u00ed pembrolizumab tam, kde je dostupn\u00fd, a generika v zemi p\u016fvodu se v\u00fdrazn\u011b li\u0161\u00ed v cen\u011b.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikace<\/h2>\n<ul>\n<li>Zn\u00e1m\u00e1 p\u0159ecitliv\u011blost na pembrolizumab nebo jakoukoli pomocnou l\u00e1tku v lahvi\u010dce<\/li>\n<li>T\u011bhotenstv\u00ed nebo pl\u00e1nov\u00e1n\u00ed t\u011bhotenstv\u00ed<\/li>\n<li>Kojen\u00ed<\/li>\n<li>Z\u00e1va\u017en\u00e9 p\u0159edexistuj\u00edc\u00ed autoimunitn\u00ed onemocn\u011bn\u00ed (relativn\u00ed; posouzen\u00ed specialistou)<\/li>\n<li>P\u0159\u00edjemci transplantovan\u00fdch solidn\u00edch org\u00e1n\u016f (relativn\u00ed; posouzen\u00ed specialistou; riziko odm\u00edtnut\u00ed transplant\u00e1tu)<\/li>\n<li>Aktivn\u00ed nekontrolovan\u00e1 infekce<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interakce s l\u00e9\u010divy<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Kombinujte s<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">\u00da\u010dinek<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Co d\u011blat<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Syst\u00e9mov\u00e9 kortikosteroidy (chronick\u00e9, ekvivalent prednisonu &gt; 10 mg\/den)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Potla\u010duj\u00ed imunitn\u00ed odpov\u011b\u010f, kterou se Keytruda sna\u017e\u00ed pos\u00edlit \u2014 m\u016f\u017ee sn\u00ed\u017eit \u00fa\u010dinnost<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Pokud mo\u017eno se vyhn\u011bte dlouhodob\u00e9mu pod\u00e1v\u00e1n\u00ed kortikosteroid\u016f. Kr\u00e1tkodob\u00e9 k\u00fary pro zvl\u00e1dnut\u00ed irAE nebo jin\u00fdch indikac\u00ed jsou st\u00e1le vhodn\u00e9.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Dal\u0161\u00ed imunosupresiva (cyklosporin, mykofenol\u00e1t, azathioprin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Stejn\u00e9 jako v\u00fd\u0161e \u2014 m\u016f\u017ee sn\u00ed\u017eit \u00fa\u010dinnost Keytrudy<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Konzultace specialistou.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u017div\u00e9 vakc\u00edny (MMR, \u017elut\u00e1 zimnice, BCG, or\u00e1ln\u00ed polio, plan\u00e9 ne\u0161tovice)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Riziko diseminovan\u00e9 infekce virem \u017eiv\u00e9 vakc\u00edny<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Kontraindikov\u00e1no b\u011bhem l\u00e9\u010dby p\u0159\u00edpravkem Keytruda a n\u011bkolik m\u011bs\u00edc\u016f po n\u00ed.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Neaktivovan\u00e9 vakc\u00edny (ka\u017edoro\u010dn\u00ed ch\u0159ipka, pneumokokov\u00e1, COVID-19, hepatitida B)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Bezpe\u010dn\u00e9 a doporu\u010den\u00e9<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Standardn\u00ed praxe.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Soub\u011b\u017en\u00e1 chemoterapie (karboplatina\/paclitaxel, lenvatinib, axitinib, dal\u0161\u00ed)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Standardn\u00ed kombinace u mnoha indikac\u00ed \u2014 aditivn\u00ed \u00fa\u010dinnost<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Specializovan\u00fd re\u017eim-specifick\u00fd.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inhibitory CTLA-4 (ipilimumab)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Kombinovan\u00e1 blok\u00e1da PD-1 + CTLA-4 zlep\u0161uje odpov\u011b\u010f u n\u011bkter\u00fdch indikac\u00ed, ale v\u00fdrazn\u011b zvy\u0161uje riziko irAE<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Specializovan\u00e1 kombinovan\u00e1 terapie s intenzivn\u00edm monitorov\u00e1n\u00edm.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Pokyny k uchov\u00e1v\u00e1n\u00ed<\/h2>\n<ul>\n<li>Skladujte neotev\u0159en\u00e9 lahvi\u010dky p\u0159i <strong>2\u20138\u00b0C<\/strong> v p\u016fvodn\u00edm obalu, chr\u00e1n\u011bn\u00e9 p\u0159ed sv\u011btlem. <strong>NEMRAZIT.<\/strong><\/li>\n<li>Neprot\u0159ep\u00e1vejte lahvi\u010dku.<\/li>\n<li>Na\u0159ed\u011bn\u00fd infuzn\u00ed roztok: stabiln\u00ed a\u017e 24 hodin v chladu nebo 6 hodin p\u0159i pokojov\u00e9 teplot\u011b; nezmrazovat.<\/li>\n<li>Poru\u0161en\u00ed chladov\u00e9ho \u0159et\u011bzce (nad 8\u00b0C po dobu v\u00edce ne\u017e 24 hodin) znehodnocuje obsah lahvi\u010dky \u2014 nepou\u017e\u00edvat.<\/li>\n<li>Uchov\u00e1vejte mimo dosah d\u011bt\u00ed a dom\u00e1c\u00edch zv\u00ed\u0159at.<\/li>\n<li>Nepou\u017eit\u00e9 lahvi\u010dky vra\u0165te do l\u00e9k\u00e1rny nebo onkologick\u00e9ho odd\u011blen\u00ed k odborn\u00e9 likvidaci.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Souvisej\u00edc\u00ed alternativy na MedsBase<\/h2>\n<p>Dal\u0161\u00ed onkologick\u00e9 l\u00e9ky skladem vedle tohoto produktu:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/anaridex\/\"><strong>Anaridex (anastrozol 1 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/xtane\/\"><strong>Xtane (exemestan 25 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/fempro\/\"><strong>Fempro (letrozol 2,5 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/letroheal\/\"><strong>Letroheal (letrozol 2,5 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tamilong\/\"><strong>Tamilong (tamoxifen 10 \/ 20 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tamodex\/\"><strong>Tamodex (tamoxifen 10 \/ 20 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tamoxilon\/\"><strong>Tamoxilon (tamoxifen 10 \/ 20 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/cytotam\/\"><strong>Cytotam (tamoxifen 10 \/ 20 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/cs\/anti-cancer-medication\/\">Prohl\u00e9dn\u011bte v\u0161echny protin\u00e1dorov\u00e9 l\u00e9ky \u2192<\/a><\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3 class=\"wp-block-heading\">V \u010dem se Keytruda li\u0161\u00ed od chemoterapie?<\/h3>\n<p>Chemoterapie p\u0159\u00edmo zab\u00edj\u00ed rychle se d\u011bl\u00edc\u00ed bu\u0148ky (n\u00e1dorov\u00e9 bu\u0148ky, ale tak\u00e9 kostn\u00ed d\u0159e\u0148, vlasov\u00e9 folikuly, v\u00fdstelku tr\u00e1vic\u00edho traktu), co\u017e zp\u016fsobuje klasick\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky jako myelosupresi, alopecii, mukozitidu a nevolnost. Keytruda <strong>aktivuje pacient\u016fv vlastn\u00ed imunitn\u00ed syst\u00e9m k rozpozn\u00e1n\u00ed a zni\u010den\u00ed n\u00e1dorov\u00fdch bun\u011bk<\/strong> \u2014 p\u0159\u00edmo nezab\u00edj\u00ed bu\u0148ky. Vedlej\u0161\u00ed \u00fa\u010dinky jsou proto z\u00e1sadn\u011b odli\u0161n\u00e9: dominuj\u00ed <strong>imunitn\u011b zprost\u0159edkovan\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (irAEs)<\/strong> \u2014 autoimunitn\u00ed reakce podobn\u00e9 reakc\u00edm v jak\u00e9mkoli org\u00e1nov\u00e9m syst\u00e9mu. V\u011bt\u0161ina pacient\u016f u\u017e\u00edvaj\u00edc\u00edch Keytruda neza\u017e\u00edv\u00e1 typick\u00fd toxick\u00fd profil chemoterapie, a\u010dkoli mnoho l\u00e9\u010debn\u00fdch re\u017eim\u016f kombinuje Keytruda s chemoterapi\u00ed.<\/p>\n<h3 class=\"wp-block-heading\">Co znamen\u00e1 testov\u00e1n\u00ed PD-L1 pro mou l\u00e9\u010dbu Keytrudou?<\/h3>\n<p>PD-L1 je protein na rakovinn\u00fdch bu\u0148k\u00e1ch, jeho\u017e mechanismus Keytruda p\u0159eru\u0161uje. Exprese PD-L1 v n\u00e1doru se m\u011b\u0159\u00ed imunohistochemicky na biopsii a uv\u00e1d\u00ed se jako <strong>TPS (Tumour Proportion Score)<\/strong> nebo <strong>CPS (Combined Positive Score)<\/strong>. Vy\u0161\u0161\u00ed exprese PD-L1 obecn\u011b p\u0159edpov\u00edd\u00e1 lep\u0161\u00ed odpov\u011b\u010f na Keytrudu, zejm\u00e9na u NSCLC (TPS \u2265 50% \u2192 monoterapie prvn\u00ed linie; 1\u201349% \u2192 druh\u00e1 linie nebo s chemoterapi\u00ed). U n\u011bkter\u00fdch indikac\u00ed (NSCLC, \u017ealude\u010dn\u00ed, d\u011blo\u017en\u00ed \u010d\u00edpek, TNBC) je testov\u00e1n\u00ed PD-L1 vy\u017eadov\u00e1no p\u0159ed l\u00e9\u010dbou. U jin\u00fdch (MSI-H\/dMMR n\u00e1dory, melanom, Hodgkin\u016fv lymfom) se Keytruda pou\u017e\u00edv\u00e1 bez ohledu na stav PD-L1.<\/p>\n<h3 class=\"wp-block-heading\">Co jsou imunitn\u011b zprost\u0159edkovan\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (irAEs) a pro\u010d jsou tak d\u016fle\u017eit\u00e9?<\/h3>\n<p>irAEs jsou dominantn\u00ed kategori\u00ed vedlej\u0161\u00edch \u00fa\u010dink\u016f Keytrudy \u2014 autoimunitn\u00ed reakce zp\u016fsoben\u00e9 nebrzd\u011bn\u00fdm imunitn\u00edm syst\u00e9mem, kter\u00fd napad\u00e1 norm\u00e1ln\u00ed tk\u00e1n\u011b. Mohou postihnout jak\u00fdkoli org\u00e1n: k\u016f\u017ei, tr\u00e1vic\u00ed trakt (kolitida), pl\u00edce (pneumonitida), j\u00e1tra (hepatitida), \u0161t\u00edtnou \u017el\u00e1zu, hypof\u00fdzu, nadledviny, slinivku p\u0159i diabetu 1. typu, ledviny, perifern\u00ed nervy, srdce (vz\u00e1cn\u011b myokarditida s vysokou mortalitou). Mohou se objevit <strong>kdykoli b\u011bhem l\u00e9\u010dby, a dokonce i m\u011bs\u00edce po posledn\u00ed d\u00e1vce<\/strong>. Z\u00e1va\u017enost se pohybuje od stupn\u011b 1 (m\u00edrn\u00e9) po stupe\u0148 4 (\u017eivot ohro\u017euj\u00edc\u00ed). <strong>V\u010dasn\u00e9 rozpozn\u00e1n\u00ed je kl\u00ed\u010dov\u00e9<\/strong> \u2014 v\u011bt\u0161ina imunitn\u011b zprost\u0159edkovan\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f (irAE) dob\u0159e reaguje na syst\u00e9mov\u00e9 kortikosteroidy, pokud jsou l\u00e9\u010deny v\u010das. Pacienti by m\u011bli m\u00edt k dispozici 24hodinov\u00e9 kontaktn\u00ed \u010d\u00edslo na onkologii a b\u00fdt pou\u010deni, aby v p\u0159\u00edpad\u011b nov\u011b vznikl\u00e9ho z\u00e1va\u017en\u00e9ho pr\u016fjmu, du\u0161nosti, \u017eloutenky, siln\u00e9 \u00fanavy, slabosti, zm\u011bny vid\u011bn\u00ed nebo bolesti na hrudi volali je\u0161t\u011b tent\u00fd\u017e den.<\/p>\n<h3 class=\"wp-block-heading\">Vyl\u00e9\u010d\u00ed m\u011b Keytruda z rakoviny?<\/h3>\n<p>U n\u011bkter\u00fdch pacient\u016f a u n\u011bkter\u00fdch indikac\u00ed vyvol\u00e1v\u00e1 Keytruda dlouhodob\u00e9 odpov\u011bdi, kter\u00e9 se mohou bl\u00ed\u017eit funk\u010dn\u00edmu vyl\u00e9\u010den\u00ed \u2014 zejm\u00e9na u pokro\u010dil\u00e9ho melanomu, MSI-H\/dMMR n\u00e1dor\u016f a Hodgkinova lymfomu, kde je nyn\u00ed p\u011btilet\u00e9 p\u0159e\u017eit\u00ed v\u00fdrazn\u00e9. U nemalobun\u011b\u010dn\u00e9ho karcinomu plic a dal\u0161\u00edch indikac\u00ed Keytruda v\u00fdznamn\u011b prodlu\u017euje p\u0159e\u017eit\u00ed u \u010d\u00e1sti pacient\u016f. <strong>Odpov\u011b\u010f je vysoce individu\u00e1ln\u00ed<\/strong> a z\u00e1vis\u00ed na typu n\u00e1doru, expresi PD-L1, stavu MSI\/TMB, p\u0159edchoz\u00ed l\u00e9\u010db\u011b, v\u00fdkonnostn\u00edm stavu a na tom, zda je Keytruda pou\u017e\u00edv\u00e1na jako monoterapie nebo v kombinaci. Prodiskutujte o\u010dek\u00e1van\u00fd v\u00fdsledek specifick\u00fd pro v\u00e1\u0161 n\u00e1dor se sv\u00fdm onkologem.<\/p>\n<h3 class=\"wp-block-heading\">Kdy uvid\u00edm, \u017ee Keytruda \u00fa\u010dinkuje?<\/h3>\n<p>Zobrazovac\u00ed odpov\u011b\u010f je obvykle poprv\u00e9 m\u011b\u0159iteln\u00e1 za <strong>9\u201312 t\u00fddn\u016f<\/strong> (po 3\u20134 cyklech). N\u011bkte\u0159\u00ed pacienti vykazuj\u00ed <strong>pseudoprogresi<\/strong> \u2014 po\u010d\u00e1te\u010dn\u00ed zd\u00e1nliv\u00e9 zv\u011bt\u0161en\u00ed na prvn\u00edm sn\u00edmku zp\u016fsoben\u00e9 infiltrac\u00ed n\u00e1doru imunitn\u00edmi bu\u0148kami, n\u00e1sledovan\u00e9 skute\u010dnou odpov\u011bd\u00ed. P\u0159ed vyhl\u00e1\u0161en\u00edm selh\u00e1n\u00ed l\u00e9\u010dby na z\u00e1klad\u011b \u010dasn\u00e9ho zobrazov\u00e1n\u00ed je nutn\u00fd odborn\u00fd \u00fasudek.<\/p>\n<h3 class=\"wp-block-heading\">Mohu dostat \u017eiv\u00e9 vakc\u00edny b\u011bhem l\u00e9\u010dby Keytrudou?<\/h3>\n<p>Ne \u2014 \u017eiv\u00e9 vakc\u00edny (MMR, \u017elut\u00e1 zimnice, BCG, or\u00e1ln\u00ed polio, plan\u00e9 ne\u0161tovice) jsou b\u011bhem l\u00e9\u010dby Keytrudou a alespo\u0148 6 m\u011bs\u00edc\u016f po posledn\u00ed d\u00e1vce kontraindikov\u00e1ny. Inaktivovan\u00e9 vakc\u00edny (ka\u017edoro\u010dn\u00ed ch\u0159ipka, pneumokok, COVID-19, hepatitida B) jsou nejen bezpe\u010dn\u00e9, ale doporu\u010den\u00e9 \u2014 onkologi\u010dt\u00ed pacienti maj\u00ed vy\u0161\u0161\u00ed riziko infekce a m\u011bli by b\u00fdt o\u010dkov\u00e1ni proaktivn\u011b.<\/p>\n<h3 class=\"wp-block-heading\">Mohu u\u017e\u00edvat kortikosteroidy p\u0159i l\u00e9\u010db\u011b Keytrudou?<\/h3>\n<p>Brief or short-term steroid courses for irAE management are appropriate and necessary. <strong>Chronic high-dose steroids<\/strong> (prednisone &gt; 10 mg\/day equivalent for prolonged periods) at baseline may suppress the immune response Keytruda is designed to enhance \u2014 oncologists try to wean these patients off steroids.<\/p>\n<h3 class=\"wp-block-heading\">Is Keytruda safe in pregnancy?<\/h3>\n<p>No \u2014 absolutely contraindicated. <strong>Pembrolizumab crosses the placenta and could disrupt fetal immune tolerance with serious consequences (stillbirth, fetal autoimmune disease).<\/strong>. Reliable contraception is mandatory throughout treatment AND for at least.<\/p>\n<h3 class=\"wp-block-heading\">4 months after the last dose<\/h3>\n<p>. Avoid breastfeeding during treatment and for 4 months after.<\/p>\n<h3 class=\"wp-block-heading\">Why is Keytruda so expensive?<\/h3>\n<p>Pembrolizumab is one of the most expensive cancer drugs globally \u2014 a single 200 mg dose at originator pricing can cost USD $10,000\u201314,000 in high-income markets, before discounts. Reasons: complex monoclonal antibody manufacturing, originator patent monopoly until 2028, high R&amp;D recoupment, premium pricing. Patient assistance programmes (Merck's ACT programme in the US, charity programmes in many countries), source-country generics where available, and emerging biosimilar pembrolizumab in some markets significantly reduce cost. Discuss financial assistance with your oncology social worker or pharmacy. <strong>How long do I stay on Keytruda?<\/strong> Depends on indication. <strong>Adjuvant therapy<\/strong>(after curative-intent surgery in melanoma, NSCLC etc.): typically 1 year (17 cycles of Q3W or 9 cycles of Q6W).<\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Ka\u017ed\u00e1 \u0161ar\u017ee je dod\u00e1v\u00e1na od <strong>v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Objedn\u00e1vky jsou expedov\u00e1ny v nen\u00e1padn\u00fdch obalech bez loga od na\u0161ich partnersk\u00fdch sklad\u016f a jsou pokryty na\u0161\u00ed <a href=\"\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>: pokud z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, za\u0161leme zdarma n\u00e1hradn\u00ed z\u00e1silku, bez dotaz\u016f.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Souvisej\u00edc\u00ed protin\u00e1dorov\u00e9 l\u00e9ky<\/h3>\n<p>Dal\u0161\u00ed onkologick\u00e9 l\u00e9ky skladem vedle tohoto produktu:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/votrient\/\">Votrient (pazopanib 200\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/imatib\/\">Imatib (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/veenat\/\">Veenat (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tamilong\/\">Tamilong (tamoxifen 10\/20 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/xtane\/\">Xtane (exemestan 25 mg)<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Inhibitor imunitn\u00ed checkpointu PD-1<br \/>\n\u2705 15+ indikac\u00ed u onkologick\u00fdch onemocn\u011bn\u00ed (melanom, NSCLC, MSI-H\/dMMR n\u00e1dory agnostick\u00e9, HNSCC, Hodgkin\u016fv lymfom, uroceli\u00e1rn\u00ed karcinom, RCC, TNBC, endometri\u00e1ln\u00ed karcinom a dal\u0161\u00ed)<br \/>\n\u2705 Intraven\u00f3zn\u00ed infuze 200 mg ka\u017ed\u00e9 3 t\u00fddny NEBO 400 mg ka\u017ed\u00fdch 6 t\u00fddn\u016f<br \/>\n\u2705 Pod\u00e1v\u00e1 se pouze v nemocnici \/ onkologick\u00e9 denn\u00ed jednotce<br \/>\n\u2705 Nutn\u00fd dohled specialisty onkologa<\/p>\n<p>Keytruda obsahuje pembrolizumab 100 mg\/4 mL (Merck \/ MSD). Humanizovan\u00e1 monoklon\u00e1ln\u00ed protil\u00e1tka, kter\u00e1 blokuje PD-1 a uvol\u0148uje imunitn\u00ed syst\u00e9m k rozpozn\u00e1n\u00ed rakovinn\u00fdch bun\u011bk. Vy\u017eaduje p\u00e9\u010di pod veden\u00edm specialisty onkologa, vstupn\u00ed staging a testov\u00e1n\u00ed biomarker\u016f (PD-L1, MSI\/dMMR) p\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby.<\/p>","protected":false},"featured_media":53354,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53353","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/53353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=53353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/53354"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=53353"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=53353"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=53353"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=53353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}